The mission of our conference is to understand and confront the issues surrounding early diagnosis and treatment of lung cancer and interstitial lung disease (ILD); and to expand the reach of practice-relevant research to medical and scientific communities nationally and abroad.

**Tuesday, October 16**

8:30  
REGISTRATION & BUFFET BREAKFAST

9:00 – 9:30  
**Welcome. C. Connery, Host**  
Conference Welcome. **J. P. Smith, I-ELCAP Advisory Board**  
Program Overview. **C. Henschke**  
I-ELCAP and IELCART Update. **C. Henschke**

9:30 – 11:00  
**Global Updates of Screening Initiatives.** Moderator: **C. Connery**  
9:30 – 9:45  
A High Risk Lung Cancer Screening Program: The Canadian Way. **H. Schmidt**  
9:45 – 10:00  
Initiatives in China. **W. Tang**  
10:00 – 10:15  
Poland and Eastern Europe. **W. Rzyman**  
10:15 – 10:30  
European Position Statement and Implementation. **J. Field**  
10:30 – 10:45  
Screening in Brazil. **R. Sales dos Santos**  
10:45 – 11:00  
IASLC Lung Cancer Screening Initiative. **J. Mulshine**

11:00 – 11:15  
COFFEE BREAK

11:15 – 12:30  
**Stage I Lung Cancer.** Moderator: **F. Grannis**  
11:15 – 11:30  
Surgical morbidity and mortality for Stage I lung cancer in CALGB. **N. Altorki**  
11:30 – 11:45  
Surgical morbidity and mortality in Stage I lung cancer in IELCART. **D. Nicastri**  
11:45 – 12:00  
Radiotherapy for Stage I. **K. Rosenzweig**  
12:00 – 12:15  
Sentinel lymph nodes in Stage I. **S. Quadri**  
12:15 – 12:30  
Tumor microenvironment and prognoses. **H. Pass**

12:30 – 1:30  
LUNCH

1:30 – 2:30  
**Preliminary findings from IELCART.** Moderator: **H. Pass**  
1:30 – 1:45  
Why the robot? **C. Connery**  
1:45 – 2:00  
Why not? **R. Flores**  
2:00 – 2:15  
What drives decisions in IELCART. **R. Yip**  
2:15 – 2:30  
Role of FNA in IELCART. **D. Yankelevitz**

2:30 – 3:30  
**Aggressiveness of Stage I Lung Cancer** Moderator: **D. Yankelevitz**  
2:30 – 2:45  
Size, grade, histology: what do we know? **E. Burks**  
2:45 – 3:00  
Neoadjuvant therapy in early stage NSCLC. **F. Hirsch**  
3:00 – 3:15  
Tumor doubling times, PET scans and prognosis. **Y. Wang, M. Siddique**  
3:15 – 3:30  
Molecular characterization and prognosis. **L. Montuenga**
Tuesday, October 16th (continued)

3:30 – 4:00  COFFEE BREAK

4:00 – 4:45  Panel Discussion of Difficult Cases. Moderator: T. Collins

4:45 – 5:30  Closed Meeting for I-ELCAP and IELCART Members

6:00 – 9:00  CONFERENCE DINNER – American Bounty at the Culinary Institute of America

Wednesday, October 17th

8:00  REGISTRATION & BUFFET BREAKFAST

8:30 – 9:45  Screening updates. Moderator: J. Mulshine
8:30 – 8:45  Quantitative Screening Report. A. Reeves
8:45 – 9:00  Why are we not performing more screening? A. McKee
9:00 – 9:15  Nodule growth? A. Jirapatnakul
9:15 – 9:30  Low-dose radiation. R. Subramaniam
9:30 – 9:45  Efficiency of ACR-LungRADS and I-ELCAP. C. Henschke

9:45 – 10:00  COFFEE BREAK

10:00 – 11:00  New Horizons. Moderator: J. Mulshine
10:00 – 10:15  Where will improved image quality take us? R. Avila
10:15 – 10:30  Lessons learned from social media. V. Krishnamurthy
10:30 – 10:45  Using AI for outreach to smokers. A. Ramos
10:45 – 11:00  AI applications in medicine. A. McGrath

11:00 – 12:00  Heart Disease and CT screening. Moderator: K. Haleem
11:00 – 11:15  Does heart size matter and how to measure it? J. Ling
11:15 – 11:30  Coronary artery disease in high-performance athletes. K. Haleem
11:30 – 11:45  Coronary contrast CT approaches. M. Yen
11:45 – 12:00  Aortic aneurysms and monitoring. A. Messina

12:00 – 12:45  LUNCH

12:45 – 1:45  Health Check. Moderator: D. Yankelevitz
12:45 – 1:00  Coverage and policy landscape. A. McGlothlin
1:00 – 1:15  Population Health Metrics for LC Screening. B. Pyenson
1:15 – 1:30  Implications of aortic valve calcifications. Y. Zhu
1:30 – 1:45  Reporting ancillary findings and legal considerations. L. Goldsmith

1:45 – 2:45  Update on VA-PALS. Moderator: C. Henschke
1:45 – 2:00  Update on VA-PALS and VALOR. D. Moghanaki
2:00 – 2:15  Implementation at the Phoenix VA. S. Aguayo
2:15 – 2:30  Development of VA QA for screening. D. Yankelevitz

2:45 – 3:30  Interstitial Lung Disease. Moderator: T. Collins
2:45 – 3:00  ILD in the community setting. H. Suseelan
3:00 – 3:15  Meta-analysis of ILD and lung cancer. M. Salvatore
3:15 – 3:30  Next generation treatments for ILD and monitoring them. M. Padilla